Methyldopa Cf

Methyldopa, the active ingredient in Methyldopa Cf, is a alpha‑2 adrenergic agonist presented as an oral formulation for oral use. It is employed to lower elevated blood pressure in adults, including patients with hypertension during pregnancy. By acting on central nervous system receptors, it reduces sympathetic nerve activity, offering a sustained antihypertensive effect.

GNH USA supplies Methyldopa Cf as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and regulatory requirements.

Methyldopa is indicated for the management of hypertension and related conditions.

- Essential hypertension: reduces systolic and diastolic pressure in patients with primary high blood pressure. - Pregnancy‑induced hypertension: provides a safe oral option for controlling blood pressure in pregnant women. - Secondary hypertension: assists in lowering blood pressure when caused by other underlying disorders.

Methyldopa may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dry mouth - Drowsiness or fatigue - Headache - Nausea or vomiting - Dizziness or light‑headedness

Serious or Rare Side Effects: - Severe hypotension - Liver dysfunction or hepatitis - Hemolytic anemia or other blood dyscrasias - Stevens‑Johnson syndrome or severe skin reactions - Agranulocytosis

When prescribing Methyldopa, clinicians should observe several precautionary measures to ensure patient safety.

- Blood pressure monitoring: regularly assess blood pressure to avoid excessive hypotension. - Liver function: evaluate hepatic enzymes before initiating therapy and periodically thereafter. - Hematologic assessment: monitor complete blood count for signs of anemia or leukopenia. - Cardiac disease: use with caution in patients with existing heart failure or conduction abnormalities. - Abrupt discontinuation: avoid sudden stopping to prevent rebound hypertension. - Store at room temperature: keep in the original packaging, protect from moisture and light.

Methyldopa can interact with other medicines, influencing its antihypertensive effect or increasing the risk of adverse events.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): may cause severe hypertension or hypertensive crisis. - Other central alpha‑2 agonists (e.g., clonidine): additive hypotensive effect. - Potent antihypertensives (e.g., ACE inhibitors, diuretics): risk of excessive blood pressure drop. - Tricyclic antidepressants: may potentiate central nervous system depression. - CNS depressants (e.g., barbiturates, alcohol): enhance sedative effects.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce antihypertensive efficacy. - Beta‑blockers: monitor for additive blood pressure lowering. - Lithium: observe lithium levels as blood pressure changes can affect renal clearance. - Oral contraceptives: may alter plasma protein binding. - Diuretics: watch for electrolyte disturbances.